Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

1. Methylphenidate

. Methylphenidate (also known as Ritalin ®) is a drug that is used in the treatment of attention deficit / hyperactivity disorder (ADHD) in children, adolescents and adults. Modafinil ( Vigil ®) is a drug used in the treatment of narcolepsy (sleeping sickness). In the study. These substances are given in the study only once and in the dosages in which is also 2014 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK. (...) Methylphenidate Top results for methylphenidate - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3

2018 Trip Latest and Greatest

2. Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects

Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects'', 1 June 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects FEATURED REVIEW Methylphenidate is an amphetamine-like psychostimulant used in attention deficit hyperactivity disorder (ADHD). Recent studies have revealed important data about the consequences of in utero exposure

2019 Prescrire

3. Methylphenidate (Ritalin) as a means of controlling classroom behaviour

Methylphenidate (Ritalin) as a means of controlling classroom behaviour Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin°) as a means of controlling classroom behaviour'', 1 May 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin°) as a means of controlling classroom behaviour Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Methylphenidate (Ritalin°) as a means of controlling classroom behaviour Too many children are overdiagnosed with attention deficit hyperactivity disorder (ADHD) simply because they are the youngest in the class and so tend to be more easily distracted and disruptive. Children are diagnosed with attention deficit with or without hyperactivity when they exhibit various non-specific symptoms such as difficulty concentrating in class, fidgetiness and impulsivity. The boundaries are unclear. At best

2019 Prescrire

4. Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. Full Text available with Trip Pro

Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with high prevalence in adulthood. There is a recognized need to assess the efficacy of psychotherapy in adult ADHD.To evaluate the efficacy of cognitive behavioral group psychotherapy (GPT) compared with individual clinical management (...) (CM) and that of methylphenidate hydrochloride compared with placebo.Prospective, multicenter, randomized clinical trial of 18- to 58-year-old outpatients with ADHD from 7 German study centers. Patients were recruited between January 2007 and August 2010, treatment was finalized in August 2011, and final follow-up assessments occurred in March 2013.Sessions of GPT and CM were held weekly for the first 12 weeks and monthly thereafter (9 months). Patients received either methylphenidate or placebo

2015 JAMA psychiatry Controlled trial quality: predicted high

5. Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials

Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials Amphetamines and methylphenidate for paediatric ADHD Search National Elf Service Search National Elf Service » » » » Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials May 24 2016 Posted by Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders, with an estimated prevalence of about 5% in school-age children (Polanczyk et al, 2007 (...) ; Polanczyk et al, 2014) and 2.5% in adults. (Simon V et al, 2009). The recommended treatment of ADHD is multimodal, including pharmacological and non-pharmacological interventions. Medications for ADHD include psychostimulant (e.g., methylphenidate and amphetamine derivatives) and non-psychostimulant drugs (e.g., atomoxetine and guanfacine). Psychostimulants are the most common drugs used for ADHD worldwide. A large body of evidence from randomised controlled trials (RCTs), summarised in several meta

2016 The Mental Elf

6. OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD

and/or diversion of Concerta compared to other formulations of methylphenidate? Assessment principles: Included trials are double-blind randomized controlled trials (RCTs) in patients 6 years or older diagnosed with ADHD and comparing OROS formulation of methylphenidate to other long or short acting formulations of MPH or other standard therapy (amphetamine or atomoxetine) available in Canada. Methylphenidate formulations available in Canada are short-acting or “immediate-release” tablets: Ritalin (...) and the generics: PMS-methylphenidate and Apo-methylphenidate; sustained-release tablets: Ritalin SR; controlled-release capsules: Biphentin. Amphetamine preparations available in Canada are short-acting or “immediate-release” tablets: Dexedrine; sustained-release spansules: Dexedrine Spansule; and extended-release dextroamphetamine capsules: Adderall XR. Strattera (atomoxetine) is a long acting, non-stimulant. Therapeutic advantage will be assessed according to the following hierarchy of health outcomes – all

2010 Therapeutics Letter

7. Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity

Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity (METHACAN) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2018 Clinical Trials

8. The Time Course of Effect of Multilayer-Release Methylphenidate Hydrochloride Capsules: A Randomized, Double-Blind Study of Adults With ADHD in a Simulated Adult Workplace Environment. (Abstract)

The Time Course of Effect of Multilayer-Release Methylphenidate Hydrochloride Capsules: A Randomized, Double-Blind Study of Adults With ADHD in a Simulated Adult Workplace Environment. The aim of this study is to assess the onset and duration of efficacy of multilayer-release methylphenidate (PRC-063) over 16 hr compared with placebo in adults with ADHD using the simulated adult workplace environment.After dose-optimization with PRC-063, participants entered a double-blind, placebo-controlled

2016 Journal of attention disorders Controlled trial quality: predicted high

9. Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality?

Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ Article Text Perspective Evidence on methylphenidate in children and adolescents with ADHD

2016 Evidence-Based Mental Health

10. Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial Full Text available with Trip Pro

Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients (...) with ADHD in Zahedan, Iran.In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven

2017 Electronic physician Controlled trial quality: uncertain

11. Sustained effects of neurofeedback and methylphenidate in ADHD children: meta-analysis

Sustained effects of neurofeedback and methylphenidate in ADHD children: meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

12. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. Full Text available with Trip Pro

Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. The prescription use of the stimulants methylphenidate and amphetamine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been increasing. In 2007, the Food and Drug Administration mandated changes to drug labels for stimulants on the basis of findings of new-onset psychosis. Whether the risk of psychosis in adolescents and young adults with ADHD differs among various stimulants has not been extensively (...) studied.We used data from two commercial insurance claims databases to assess patients 13 to 25 years of age who had received a diagnosis of ADHD and who started taking methylphenidate or amphetamine between January 1, 2004, and September 30, 2015. The outcome was a new diagnosis of psychosis for which an antipsychotic medication was prescribed during the first 60 days after the date of the onset of psychosis. To estimate hazard ratios for psychosis, we used propensity scores to match patients who

2019 NEJM

13. Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood

Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 13. 2000 Authors' objectives To provide guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. Authors' conclusions Guidance 1.1 Methylphenidate is recommended for use as part

2000 Health Technology Assessment (HTA) Database.

14. Cardiovascular safety of methylphenidate

usual caution if have congenital heart disease. RT @Mental_Elf: Ritalin risk-benefit should be carefully considered, particularly in children with mild ADHD https:… The risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD El metilfenidato debe ser prescrito sólo después de una cuidadosa evaluación del riesgo cardiovascular #TDAH RT @Mental_Elf: Methylphenidate should be prescribed only after careful evaluation of cardiovascular risk (...) Cardiovascular safety of methylphenidate Cardiovascular safety of methylphenidate - National Elf Service Search National Elf Service Search National Elf Service » » » » Cardiovascular safety of methylphenidate Jun 20 2016 Posted by Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neuropsychiatric condition, characterised by age-inappropriate, pervasive and impairing levels of inattention and/or hyperactivity-impulsivity (American Psychiatric Association, 2013). Pharmacological

2016 The Mental Elf

15. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial. Full Text available with Trip Pro

Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial. Intra-individual variability in reaction time (IIV-RT) is common in individuals with attention-deficit/hyperactivity disorder (ADHD). It can be improved by stimulants. However, the effects of atomoxetine on IIV-RT are inconclusive. We aimed to investigate the effects of atomoxetine on IIV-RT (...) , and directly compared its efficacy with methylphenidate in adults with ADHD.An 8-10 week, open-label, head-to-head, randomized clinical trial was conducted in 52 drug-naïve adults with ADHD, who were randomly assigned to two treatment groups: immediate-release methylphenidate (n=26) thrice daily (10-20 mg per dose) and atomoxetine once daily (n=26) (0.5-1.2 mg/kg/day). IIV-RT, derived from the Conners' continuous performance test (CCPT), was represented by the Gaussian (reaction time standard error, RTSE

2016 Journal of psychopharmacology (Oxford, England) Controlled trial quality: uncertain

16. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study (Abstract)

Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use.Ninety-four children and adolescents (ages 8-18 years) who had been (...) treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners' Teacher Rating Scale-Revised: Short

2019 EvidenceUpdates

17. Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. Full Text available with Trip Pro

Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. HLD200, an oral, once-daily, evening-dosed, delayed-release, and extended-release methylphenidate (DR/ER-MPH), was designed to provide efficacy from the early morning, throughout the day, and into the evening to individuals with attention-deficit

2019 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

18. Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study. (Abstract)

Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study. Disruptive mood dysregulation disorder (DMDD) is characterized by nonepisodic irritability and has a high rate of comorbidity with attention-deficit/hyperactivity disorder (ADHD). This is the first study to explore the effects of aripiprazole combined with methylphenidate on clinical symptoms and cognitive functions (...) in patients with DMDD and ADHD.Patients with DMDD and ADHD (the DMDD-ADHD Group, n = 24; aged 7-17 years) completed a 6-week, open-label trial of aripiprazole and methylphenidate. The pre- and posttreatment outcome measures included the parent-rated Swanson, Nolan, and Pelham Scale-version IV, Child Behavior Checklist, and self-reported Beck Youth Inventories-II, as well as a neuropsychological battery composed of the Children's Color Trail Test and Conner's Continuous Performance Test. The comparison

2018 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

19. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder Article Text Methods

2017 Evidence-Based Medicine

20. Methylphenidate

, Ritalin , Methylin , Concerta II. Indications: Methylphenidate (Ritalin) ( ) Depression in medically ill elderly patients Enhanced pain control in patients on s III. Contraindications See s below (ask related PMH, and screen on exam) Consider an EKG before prescribing s or disorder Pregnancy IV. Pharmacokinetics: Methylphenidate Immediate Release: Ritalin-IR, Methylin IR Onset of action: within 20 to 30 minutes of dose (up to 60 minutes) Peaks at 1.9 hours on average Duration: 3 to 6 hours Immediate (...) Release: Focalin (Dexmethylphenidate) D-isomer of Ritalin (l-isomer is inactive) Prescribed at half dose of Ritalin Same pharmacokinetics as immediate release Methylphenidate Fewer s but more e pain than with Methylphenidate Long-Acting: Ritalin-LA Duration: 8 hours Biphasic release Immediate release: 50% Modified release beads: 50% Preferred over Ritalin SR Long-Acting: Ritalin-SR, Metadate ER, Methylin ER Onset of action: within 90 minutes of dose Peaks at 3 hours on average Duration: 5-8 hours

2018 FP Notebook